Skip to main content
Journal cover image

Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.

Publication ,  Journal Article
Liddle, RA; Gertz, BJ; Kanayama, S; Beccaria, L; Gettys, TW; Taylor, IL; Rushakoff, RJ; Williams, VC; Coker, LD
Published in: J Clin Endocrinol Metab
May 1990

A cholecystokinin (CCK) receptor antagonist, MK-329, was used to explore the physiological role of CCK in regulating pancreatic endocrine function in humans. The ability of CCK to increase plasma pancreatic polypeptide (PP) concentrations and blockade of this effect with MK-329 were evaluated in a double blind, balanced, four-period cross-over study. Eight subjects received single oral doses of 0.5, 2, or 10 mg MK-329 or placebo, followed by an iv infusion of CCK-8 (34 ng/kg.h). In placebo-treated subjects, PP increased from basal levels of 70 +/- 15 (+/- SE) to peak values of 291 +/- 58 pg/mL after CCK infusion (P less than 0.05 compared to basal). This increase in plasma PP concentration was inhibited in a dose-dependent fashion by MK-329, with 10 mg antagonizing the stimulatory effect of CCK infusion by nearly 80%. Second, the effect of MK-329 on meal-stimulated pancreatic endocrine responses was evaluated by giving placebo or 10 mg MK-329 2 h before ingestion of a mixed meal. Eight subjects were treated in a randomized two-period cross-over fashion. With placebo treatment, peak postprandial plasma insulin, glucagon, and glucose concentrations were 101 +/- 8 microU/mL, 195 +/- 15 pg/mL, and 150 +/- 10 mg/dL, respectively (all P less than 0.05). The integrated PP response following the meal was 56.3 +/- 11.1 ng/mL.minute. With MK-329 treatment, the integrated PP concentration was reduced to 33.9 +/- 2.2 ng/mL.min (P less than 0.05 compared to placebo treatment). Mean postprandial insulin, glucagon, and glucose concentrations did not differ between placebo and MK-329 treatments. We conclude that CCK receptor blockade with 10 mg MK-329 does not alter plasma insulin, glucagon, or glucose responses to a mixed meal. However, the observation that physiological concentrations of CCK increase plasma levels of PP, and the finding that CCK receptor blockade selectively attenuates the postprandial increase in plasma PP concentrations support a physiological role for CCK in regulating PP secretion.

Duke Scholars

Published In

J Clin Endocrinol Metab

DOI

ISSN

0021-972X

Publication Date

May 1990

Volume

70

Issue

5

Start / End Page

1312 / 1318

Location

United States

Related Subject Headings

  • Receptors, Cholecystokinin
  • Pancreatic Polypeptide
  • Male
  • Islets of Langerhans
  • Insulin
  • Humans
  • Glucagon
  • Endocrinology & Metabolism
  • Eating
  • Devazepide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liddle, R. A., Gertz, B. J., Kanayama, S., Beccaria, L., Gettys, T. W., Taylor, I. L., … Coker, L. D. (1990). Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab, 70(5), 1312–1318. https://doi.org/10.1210/jcem-70-5-1312
Liddle, R. A., B. J. Gertz, S. Kanayama, L. Beccaria, T. W. Gettys, I. L. Taylor, R. J. Rushakoff, V. C. Williams, and L. D. Coker. “Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.J Clin Endocrinol Metab 70, no. 5 (May 1990): 1312–18. https://doi.org/10.1210/jcem-70-5-1312.
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Gettys TW, Taylor IL, et al. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab. 1990 May;70(5):1312–8.
Liddle, R. A., et al. “Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.J Clin Endocrinol Metab, vol. 70, no. 5, May 1990, pp. 1312–18. Pubmed, doi:10.1210/jcem-70-5-1312.
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Gettys TW, Taylor IL, Rushakoff RJ, Williams VC, Coker LD. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab. 1990 May;70(5):1312–1318.
Journal cover image

Published In

J Clin Endocrinol Metab

DOI

ISSN

0021-972X

Publication Date

May 1990

Volume

70

Issue

5

Start / End Page

1312 / 1318

Location

United States

Related Subject Headings

  • Receptors, Cholecystokinin
  • Pancreatic Polypeptide
  • Male
  • Islets of Langerhans
  • Insulin
  • Humans
  • Glucagon
  • Endocrinology & Metabolism
  • Eating
  • Devazepide